1. Articles from ncbi.nlm.nih.gov

  2. 1-24 of 1681 1 2 3 4 ... 68 69 70 »
    1. LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis.

      LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis.

      Clin Cancer Res. 2018 Jun 20;:

      Authors: Dorneburg C, Fischer M, Barth TFE, Mueller-Klieser W, Hero B, Gecht J, Carter DR, De Preter K, Mayer B, Christner L, Speleman F, Marshall GM, Debatin KM, Beltinger C

      Read Full Article
      Mentions: MYCN LDH
    2. Somatic late effects in 5-year survivors of neuroblastoma: A population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.

      Somatic late effects in 5-year survivors of neuroblastoma: A population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.

      Int J Cancer. 2018 Jun 21;:

      Authors: Norsker FN, Rechnitzer C, Cederkvist L, Tryggvadottir L, Madanat-Harjuoja LM, Øra I, Thorarinsdottir HK, Vettenranta K, Bautz A, Schrøder H, Hasle H, Winther JF

      Read Full Article
    3. Olive ingestion causing a false suspicion of relapsed neuroblastoma: A case of "oliveblastoma?"

      Olive ingestion causing a false suspicion of relapsed neuroblastoma: A case of "oliveblastoma?"

      Pediatr Blood Cancer. 2018 Jun 19;:e27248

      Authors: Flynn N, LeFebvre A, Messahel B, Hogg SL

      Abstract Measurement of the urine catecholamine metabolites homovanillic acid (HVA) and vanillylmandelic acid (VMA) are the standard method for detecting disease recurrence in neuroblastoma.

      Read Full Article
    4. Selective T cell-depleted haploidentical hematopoietic stem cell transplantation for relapsed/refractory neuroblastoma.

      Selective T cell-depleted haploidentical hematopoietic stem cell transplantation for relapsed/refractory neuroblastoma.

      Pediatr Transplant. 2018 Jun 19;:e13240

      Authors: Liu APY, Lee PPW, Kwok JSY, Leung RYY, Chiang AKS, Ha SY, Cheuk DKL, Chan GCF

      Abstract Relapsed/refractory NB carries a bleak outcome, warranting novel treatment options. HaploHSCT induces a graft-versus-NB effect via natural killer cell alloreactivity.

      Read Full Article
    5. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.

      Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.

      Clin Nucl Med. 2018 Jun 19;:

      Authors: Willegaignon J, Crema KP, Oliveira NC, Pelissoni RA, Coura-Filho GB, Sapienza MT, Buchpiguel CA

      Read Full Article
    6. Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.

      Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.

      J Adv Pract Oncol. 2017 Jan-Feb;8(1):44-55

      Authors: Armideo E, Callahan C, Madonia L

      Abstract Despite more intensive therapy, high-risk neuroblastoma continues to be a challenging disease to treat. Postconsolidation immunotherapy has been studied for many years and has proven to be effective in clinical trials.

      Read Full Article
    7. Lymph microvascularization as a prognostic indicator in neuroblastoma.

      Lymph microvascularization as a prognostic indicator in neuroblastoma.

      Oncotarget. 2018 May 25;9(40):26157-26170

      Authors: Tadeo I, Gamero-Sandemetrio E, Berbegall AP, Gironella M, Ritort F, Cañete A, Bueno G, Navarro S, Noguera R

      Abstract Neuroblastoma is the most common extra-cranial solid pediatric cancer and causes approximately 15% of all childhood deaths from cancer.

      Read Full Article
    8. Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.

      Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.

      J Natl Compr Canc Netw. 2018 Jun;16(6):683-691

      Authors: Eterovic AK, Maher OM, Chandra J, Chen K, Huse J, Zaky W

      Abstract Metachronous neoplasms have rarely been reported in patients with neuroblastoma.

      Read Full Article
      Mentions: ALK
    9. Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.

      Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.

      Cancer. 2018 Jun 11;:

      Authors: Zheng DJ, Krull KR, Chen Y, Diller L, Yasui Y, Leisenring W, Brouwers P, Howell R, Lai JS, Balsamo L, Oeffinger KC, Robison LL, Armstrong GT, Kadan-Lottick NS

      Read Full Article
    10. President Signs STAR Act for Kids' Cancers.

      President Signs STAR Act for Kids' Cancers.

      Cancer Discov. 2018 Jun 07;:

      Authors:

      Abstract On June 5, President Donald Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research Act, which aims to support pediatric cancer research by expanding the collection of patient biospecimens and records, improving surveillance, and investigating pediatric survivorship.

      PMID: 29880581 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Treatment
    11. Predicting clinical outcome of neuroblastoma patients using an integrative network-based approach.

      Predicting clinical outcome of neuroblastoma patients using an integrative network-based approach.

      Biol Direct. 2018 Jun 07;13(1):12

      Authors: Tranchevent LC, Nazarov PV, Kaoma T, Schmartz GP, Muller A, Kim SY, Rajapakse JC, Azuaje F

      Abstract BACKGROUND: One of the main current challenges in computational biology is to make sense of the huge amounts of multidimensional experimental data that are being produced.

      Read Full Article
    12. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.

      Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.

      Oncogene. 2018 Jun 07;:

      Authors: Boboila S, Lopez G, Yu J, Banerjee D, Kadenhe-Chiweshe A, Connolly EP, Kandel JJ, Rajbhandari P, Silva JM, Califano A, Yamashiro DJ

      Read Full Article
      Mentions: MYCN
    13. Age distribution and age-related outcomes of olfactory neuroblastoma: a population-based analysis.

      Age distribution and age-related outcomes of olfactory neuroblastoma: a population-based analysis.

      Cancer Manag Res. 2018;10:1359-1364

      Authors: Yin Z, Wang Y, Wu Y, Zhang X, Wang F, Wang P, Tao Z, Yuan Z

      Abstract Objective: The objective of the study was to describe the age distribution and to evaluate the role of prognostic value of age on survival in patients diagnosed with olfactory neuroblastoma (ONB). A population-based retrospective analysis was conducted.

      Read Full Article
    14. Comparison of long-term prognosis of laparoscopic and open adrenalectomy for local adrenal neuroblastoma in children.

      Comparison of long-term prognosis of laparoscopic and open adrenalectomy for local adrenal neuroblastoma in children.

      Pediatr Surg Int. 2018 Jun 07;:

      Authors: Yao W, Dong K, Li K, Zheng S, Xiao X

      Abstract OBJECTIVE: To investigate and compare long-term outcomes in children undergoing laparoscopic or open adrenalectomy for local adrenal neuroblastoma.

      Read Full Article
    15. Neonatal neuroblastoma 4s with diffuse liver metastases (Pepper syndrome) without an adrenal/extraadrenal primary identified on imaging.

      Neonatal neuroblastoma 4s with diffuse liver metastases (Pepper syndrome) without an adrenal/extraadrenal primary identified on imaging.

      J Radiol Case Rep. 2018 Mar;12(3):18-27

      Authors: Chaturvedi A, Katzman PJ, Franco A

      Abstract We report the imaging appearances of a case of pathologically proven, neonatal neuroblastoma 4S with diffuse hepatic metastatic involvement at presentation. Patient had an abnormal appearing liver both by ultrasound and MR.

      Read Full Article
      Mentions: Imaging MIBG
    16. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.

      Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.

      Oncoimmunology. 2018;7(6):e1433518

      Authors: Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, Lavarello C, Sinibaldi M, Weber G, Del Bufalo F, Giorda E, Scarsella M, Petrini S, Pagliara D, Locatelli F, De Angelis B, Caruana I

      Read Full Article
    17. Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.

      Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.

      J Cancer Stem Cell Res. 2017;5:

      Authors: Poniewierska-Baran A, Rajewska-Majchrzak J, Ratajczak MZ

      Abstract The erythropoietin receptor (EpoR) is expressed by cells from the erythroid lineage; however, evidence has accumulated that it is also expressed by some other non-hematopoietic tissues including several solid tumor cells and proposed candidates for cancer stem cells. This is an important concern, because recombinant erythropoietin (EPO) is frequently employed in cancer patients as a drug to ameliorate anemia related to chemo/radiotherapy. In our studies, we employed three human neuroblastoma ...

      Read Full Article
      Mentions: Radiotherapy
    18. miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10.

      miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10.

      Biomed Pharmacother. 2018 Jul;103:1312-1318

      Authors: Wang X, Li J, Xu X, Zheng J, Li Q

      Abstract Although the treatment strategies for neuroblastoma (NB) develop rapidly, a considerable number of patients could not benefit from chemotherapy. Here, we revealed a miR-129-MYO10 axis that regulated neuroblastoma growth and chemosensitivity.

      Read Full Article
    19. Convolutional Deep Belief Network with Feature Encoding for Classification of Neuroblastoma Histological Images.

      Convolutional Deep Belief Network with Feature Encoding for Classification of Neuroblastoma Histological Images.

      J Pathol Inform. 2018;9:17

      Authors: Gheisari S, Catchpoole DR, Charlton A, Kennedy PJ

      Abstract Background: Neuroblastoma is the most common extracranial solid tumor in children younger than 5 years old. Optimal management of neuroblastic tumors depends on many factors including histopathological classification.

      Read Full Article
    20. Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.

      Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.

      Cancers (Basel). 2018 May 31;10(6):

      Authors: Nguyen T, Avci NG, Shin DH, Martinez-Velez N, Jiang H

      Abstract With the progress of immunotherapy in cancer, oncolytic viruses (OVs) have attracted more and more attention during the past decade.

      Read Full Article
    21. Association of Common Genetic Variants in Pre-microRNAs and Neuroblastoma Susceptibility: A Two-Center Study in Chinese Children.

      Association of Common Genetic Variants in Pre-microRNAs and Neuroblastoma Susceptibility: A Two-Center Study in Chinese Children.

      Mol Ther Nucleic Acids. 2018 Jun 01;11:1-8

      Authors: He J, Zou Y, Liu X, Zhu J, Zhang J, Zhang R, Yang T, Xia H

      Abstract Neuroblastoma is a commonly occurring extracranial pediatric solid tumor without defined etiology. Polymorphisms in pre-miRNAs have been demonstrated to associate with the risk of several cancers.

      Read Full Article
    1-24 of 1681 1 2 3 4 ... 68 69 70 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video